Prodotti competitors / Area Oncology
Europe - Positive CHMP Opinion for for Roche's Tecentriq's subcutaneous formulation in all IV indications
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
Roche has announced the EMA's CHMP has granted a positive Opinion for its subcutaneous injection of Tecentriq (atezolizumab), in all its appoved IV indications.
This approval is based on pivotal data from the Phase IB/III IMscin001 study, which showed comparable levels of Tecentriq in the blood, when administered subcutaneously, and a safety and efficacy profile consistent with the IV formulation.
As a reminder, Tecentriq is already approved in Urothelial carcinoma (UC), Non-small cell lung cancer (NSCLC), Small cell lung cancer (SCLC), Hepatocellular carcinoma (HCC) and Triple-negative breast cancer (TNBC).
Reference link: Roche press release
Grazie per il tuo feedback!